At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 21 enrolled
Drug / intervention
MGD014biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Study to Evaluate the Safety, Immunologic and Virologic Responses of MGD014 Therapy in HIV-Infected Individuals on Suppressive Antiretroviral Therapy
In Brief
A Phase 1 clinical trial evaluating MGD014 for HIV-1-infection. Completed, enrolled 21 participants across 1 site.
Detailed Summary
This is a Phase 1, open-label single-center study to determine the safety of MGD014 in participants with human immunodeficiency virus (HIV) infection on stable suppressive antiretroviral therapy (ART).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV-1-infection
CountriesUnited States
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
First PostedJun 2018
Enrollment StartSep 2018
Primary CompletionSep 2021
TodayJul 2026
First PostedJun 27, 2018
Enrollment StartSep 25, 2018
Primary CompletionSep 28, 2021
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 8.0 years ago
Interventions
MGD014biological
HIV-1 x CD3 bispecific DART molecule